Telormedix completes Phase II trial of Vesimune for carcinoma in situ of the bladder

Switzerland-based biopharmaceutical firm Telormedix has completed an open-label Phase II clinical trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news